Calluna Pharma’s Post

🌟 𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐍𝐞𝐰𝐬 𝐢𝐧 𝐈𝐦𝐦𝐮𝐧𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲 🌟 The field of immunotherapy is advancing rapidly with the revolutionizing impact of complement proteins. Recent FDA approvals like danicopan mark significant milestones in complement-related therapy. Sino Biological, Inc.'s suite of recombinant complement proteins and antibodies are propelling novel treatments forward in immunotherapy. Explore our latest offering 👉 https://lnkd.in/ejyzeZPT And join the journey towards innovative solutions in healthcare! 💡💊🔬 #Immunotherapy #ComplementProteins #HealthcareInnovation 🚀

As we approach the upcoming Presidential Election in the United States, it's essential to spotlight a critical issue: drug pricing and medicine access. Biosimilars, which have been pivotal since their introduction in 2015, have already saved the U.S. healthcare system $36 billion and significantly increased market share, especially in oncology. Despite these successes, challenges remain, such as low penetration in some therapeutic areas and adoption barriers. Addressing these can involve policy shifts, raising awareness, and dispelling misconceptions to ensure a sustainable and cost-efficient biosimilar market. Together, we can strive for optimized patient care while reducing healthcare costs. Learn more in our latest blog post: https://lnkd.in/g2GxcS-d #PassionForHealth #Biosimilars

It is essential to understand the urgency of ensuring that the business of creating quality-assured, safe and effective biosimilars is both feasible and sustainable. Only then, through free-market competition, can we help more patients access their biological medicines more quickly - AKA NOW! #biologics #biosimilars #biotech #regulatoryreliance #accessmatters #accessforall #HealthForAll #InnovatingAccess #PassionForHealth #GlobalBiosimilarsWeek, #GBW24

In the run up to World Health Day, take a look at how private equity and venture capital helps to support Europe’s most innovative healthcare and life sciences businesses focused on cancer care. Read more on Acerta Pharma B.V. (A member of the AstraZeneca Group), Algeta ASA, argenx, BioNTech SE and Immatics. Explore our dedicated page with more than 220 success stories ➡️ https://lnkd.in/ec3A-mrA   #InvestEurope #PrivateEquity #VentureCapital #BuildingBetterBusinesses #SuccessStories #WorldHealthDay #Healthcare #LifeSciences

In a recent CRA webinar on evolving business models for DTx (Digital Therapeutics) Rhett Johnson and Andy Parece discussed with a panel of industry leaders, Richard DeNunzio, Omar Manejwala, M.D., and Brion Raymond, how events in the past year, from introduction of new HSPCS billing codes to Pear Therapeutics’ bankruptcy and the transition of some DTx manufacturers to alternative business models, impact their companies. Each panelist discussed business models their company is employing, including prescription digital therapeutics, collaboration with employers to fund solutions and with pharma companies to collaborate partner in research and commercialization. The discussion covered the drivers behind the choice of each business model as well as their advantages, and showed how they are related to the specific product, indication and available clinical evidence base. To learn more and watch the webinar recording, click here: https://lnkd.in/gjdbCBTd #DigitalTherapeutics

This November, leading experts from the global fibrosis community will gather at the 𝟴𝘁𝗵 𝗔𝗻𝘁𝗶𝗳𝗶𝗯𝗿𝗼𝘁𝗶𝗰 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗦𝘂𝗺𝗺𝗶𝘁, the go-to forum for cross-fibrosis disease insights across different organs. Join your community to harness transferable lessons to accelerate your own research and development With 𝗣𝗳𝗶𝘇𝗲𝗿, 𝗡𝗼𝘃𝗮𝗿𝘁𝗶𝘀, 𝗠𝗲𝗿𝗰𝗸, 𝗚𝗦𝗞, 𝗧𝗮𝗸𝗲𝗱𝗮, 𝗡𝗼𝘃𝗼 𝗡𝗼𝗿𝗱𝗶𝘀𝗸, 𝗔𝗿𝗱𝗮 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 and 𝗢𝗰𝗵𝗿𝗲 𝗕𝗶 already confirmed to attend, and the recent 𝗟𝗶𝗹𝗹𝘆 𝗶𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗶𝗻 𝗔𝗿𝗱𝗮 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀, it’s clear that biopharma are doubling down on fibrosis in 2024. What innovations will emerge in 2025? ✨ Spotlight Session: Hear from 𝗔𝗱𝗮𝗺 𝗙𝗿𝗲𝘂𝗻𝗱, 𝗖𝗵𝗶𝗲𝗳 𝗘𝘅𝗲𝗰𝘂𝘁𝗶𝘃𝗲 𝗢𝗳𝗳𝗶𝗰𝗲𝗿 𝗼𝗳 𝗔𝗿𝗱𝗮 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 as he shares “𝘌𝘹𝘱𝘭𝘰𝘳𝘪𝘯𝘨 𝘈𝘋𝘊-𝘔𝘦𝘥𝘪𝘢𝘵𝘦𝘥 𝘋𝘦𝘱𝘭𝘦𝘵𝘪𝘰𝘯 𝘰𝘧 𝘗𝘢𝘵𝘩𝘰𝘨𝘦𝘯𝘪𝘤 𝘍𝘪𝘣𝘳𝘰𝘣𝘭𝘢𝘴𝘵𝘴 𝘢𝘴 𝘢 𝘛𝘩𝘦𝘳𝘢𝘱𝘦𝘶𝘵𝘪𝘤 𝘚𝘵𝘳𝘢𝘵𝘦𝘨𝘺 𝘧𝘰𝘳 𝘍𝘪𝘣𝘳𝘰𝘴𝘪𝘴” Explore the full event guide to see the full list of topics covered: https://ter.li/f9osmu This Friday, October 11 marks your final chance to save on your registration to the only industry focused summit dedicated to accelerating the development of transformative, disease-modifying antifibrotic therapeutics Don’t miss this opportunity to be at the forefront of antifibrotic drug development. 📅 Date: November 19-21, 2024 📍 Location: Boston, MA 🔗 Register Here: https://ter.li/wncpx0 #fibrosis #antifibrotic #AFDD #antifibrotic #drugdevelopment #drugdiscovery #conference #fibrosisconference

The Digital Assessment Xchange (DAX) is an integrated healthcare research platform for the outcomes assessment of patients with cancers. DAX collects longitudinal 'community based' PROMs, Patient Experience & Indirect Costs outside the routine doctor consultation. DaSH Global makes the data available to pharmaceutical companies. Sponsoring clients can submit protocols for approval and DaSH will provide full analytical services via our team of real-world evidence research specialists. Find out more by visiting https://lnkd.in/eMCKwa84 Or, contact us on info@dash-global.com DaSH Global: Improving Outcomes. Transforming Lives. Bridging The Gap Between People, Health & Pharma #HealthcareResearch #PatientOutcomes #LungCancer #Mesothelioma #LongitudinalStudies #RWE #RWD #HEOR #Pharma #DrugDiscovery Vivienne Law Andrew Turner Lee Wemyss Mesothelioma UK HASAG Asbestos Disease Support Lung Cancer Nursing UK (LCNUK)

🎯 The approval of drugs with a new “target” or mechanism of action is a measure of 𝗺𝗲𝗱𝗶𝗰𝗮𝗹 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 in a certain disease area. 💊 In 𝗲𝗻𝗱𝗼𝗺𝗲𝘁𝗿𝗶𝗼𝘀𝗶𝘀, a disease affecting more than 190 million women worldwide, the last drug with a novel target was approved by the FDA 𝗺𝗼𝗿𝗲 𝘁𝗵𝗮𝗻 𝟯𝟱 𝘆𝗲𝗮𝗿𝘀 𝗮𝗴𝗼 - in January 1989, before the fall of the Berlin wall. 💡 In our new 𝗪𝗵𝗶𝘁𝗲 𝗣𝗮𝗽𝗲𝗿, we analyze the reasons behind this sobering statistic. And we highlight collaborative approaches to 𝗮𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗲 the development of much-needed new therapies for endometriosis. ➡️ More information here: https://lnkd.in/gZV5ZXzF (By way of background: During the 5-year period from 2019 to 2023, the FDA approved a total of 65 drugs with novel targets against other indications, ranging from chronic cough to COVID-19 and cancer.) #endometriosis #adenomyosis #innovation #drugdevelopment #biotech #pharma #collaboration #womenshealth #healthcare #medicine

Last week, Andrew Cummins and Mathieu Loiseau attended the World Orphan Drug Congress Europe in Barcelona, connecting with biotech leaders and sharing insights and best practices to expand access to their innovative, life-changing medicines across Europe. Here are some of their key takeaways: • From January 2025, all new ATMPs and oncology medicines will require a joint clinical assessment (JCA) at the European level, with further details still emerging. • Payors, regulators, and pharma/biotech companies need to continue to harmonise patient engagement activities to ensure the development of new treatments, devices, and health systems. • To increase participation and retention, and to reduce the burden on families, CROs should consider decentralised clinical trials more often. If you want to reach out to the team to discuss further, visit: https://lnkd.in/e7XfVg4M #WODC #OrphanDrugs #WODCBarcelona #RareDisease

Proud to share with you today the release of our Group’s integrated annual report. In all the countries where Servier distributes its medicines, we have managed to make significant progress especially in the fight against #cancer and have continued to pursue advances in #cardiovascular and #metabolic #diseases, despite the economic and geopolitical challenges our industry faced in 2023. 🚀 Our efforts have been rewarded with market authorizations and have resulted in a second-place ranking in the annual PatientView report in #oncology. 🔬 This year was also marked by the opening of our new R&D Institute at Paris-Saclay, which signifies a shift towards innovation and collaboration. 🌱 Improving patient health becomes even more meaningful when we also care about the health of the planet. Our commitment to a positive societal impact is thus reflected in our #Servier2030 strategy, aiming for a substantial reduction in our carbon footprint. 🏆 We also celebrate our corporate culture, recognized by Top Employer Europe and Great Place To Work® certifications. A huge THANK YOU to our teams all over the world, whose #commitment and passion are at the heart of these successes. Together, we are moving towards a future where the health of patients and the planet is our priority.   Our integrated Annual Report is much more than a corporate document: it's an invitation to explore our mission, our values, our achievements and our vision. To know more : https://lnkd.in/e8TZXfPb #WeAreServier #Innovation #SustainableHealth #AnnualReport #ParisSaclay #RnD